Thank you very much, Mr. Chair.
Like Ms. Wasylycia-Leis, I am also my party's health critic. Basically, she expressed what we are all feeling. Since the regime was first implemented, only one drug has been shipped overseas for humanitarian purposes. In an effort to resolve this issue, she tabled Bill C-393. However, you have looked at the proposed legislation and you indicated to us during your opening remarks that this option presents a number of risks, as we feel it does. In fact, you do not believe that the solution she is advocating is the right one.
As we consider Bill C-393, Mr. Chair, we also need to ask ourselves why a number of NGOs believe the regime is not working. We need to look at whether the regime can be made more flexible. That's why we came up with a list of about twenty potential witnesses, to help us conduct a more in-depth study and look beyond Bill C-393. I hope committee members will agree to this proposal, Mr. Chair. I really think that we need to take a closer look at this regime and ask the questions that need to be asked. It has been in place for some time now and the only example that applies is the case of Rwanda and Apotex.
Ms. Downie, you stated in your closing remarks that the regime is working. Several NGOs would disagree with your assessment and would argue that only one drug has been exported as a result of the CAMR mechanism. So then, how can you claim the regime is working?